MedlinePlus a611021 ATC code L01DB09 (WHO) CAS ID 56124-62-0 | Routes of
administration Intravesical Molar mass 723.644 g/mol | |
 | ||
AHFS/Drugs.com Consumer Drug Information Pregnancy
category US: C (Risk not ruled out) Legal status In general: ℞ (Prescription only) | ||
Valrubicin how to pronounce it
Valrubicin (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.
Contents
It was originally launched as Valstar in the U.S. in 1999 for intravesical therapy of Bacille Calmette-Guérin (BCG)-refractory carcinoma in situ of the urinary bladder in patients in whom cystectomy would be associated with unacceptable morbidity or mortality; however, it was voluntarily withdrawn in 2002 due to manufacturing issues. Valstar was relaunched on September 3, 2009.
Valrubicin meaning
Side effects
References
Valrubicin Wikipedia(Text) CC BY-SA